5-Year follow-up of sentinel node negative breast cancer patients
A.Y. de Kanter(Rotterdam University of Applied Sciences), Alexander M.M. Eggermont(University Medical Center Utrecht), Ine Burgmans(University Medical Center Utrecht), Michel W.J.M. Wouters(The Netherlands Cancer Institute), M. Menke-Pluymers(Erasmus MC Cancer Institute), A.N. van Geel(Erasmus MC)
Cited by 49
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k